Boston-based MPM Capital, an investment firm focused on life sciences companies, has raised $140 million for its fifth BioVentures fund, according to regulatory filings. Earlier reports pegged the deal at $69.1 million, but the company amended its original filing this afternoon to indicate the higher total. The firm declined to comment further on the new funding. MPM’s $552 million BioVentures IV fund led a $35 million series B round at the end of January for Alnara Pharmaceuticals, a Cambridge, MA, developer of protein-based treatments for metabolic diseases.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
